CEACAM5 positive	Gastric Cancer	CEACAM5 positive	Gastric Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 positive	Lung Cancer	CEACAM5 positive	Lung Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 positive	Colorectal Cancer	CEACAM5 positive	Colorectal Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 expression	Lung Non-Squamous Non-Small Cell Cancer	CEACAM5 expression	Lung Non-Squamous Non-Small Cell Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 expression	Gastric Cancer	CEACAM5 expression	Gastric Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 expression	Solid Tumor	CEACAM5 expression	Solid Tumor	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	SAR408701 Sensitive: C3 – Early Trials SAR408701 Sensitive : C3	SAR408701 Sensitive: C3 – Early Trials SAR408701 Sensitive : C3
CEACAM5 overexpression	Gastric Cancer	CEACAM5 overexpression	Gastric Cancer	SAR408701 Sensitive: C3 – Early Trials SAR408701 Sensitive : C3	SAR408701 Sensitive: C3 – Early Trials SAR408701 Sensitive : C3
CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab + SAR408701 Sensitive: C3 – Early Trials pembrolizumab + SAR408701 Sensitive : C3	pembrolizumab + SAR408701 Sensitive: C3 – Early Trials pembrolizumab + SAR408701 Sensitive : C3
CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	ramucirumab + SAR408701 Sensitive: C3 – Early Trials ramucirumab + SAR408701 Sensitive : C3	ramucirumab + SAR408701 Sensitive: C3 – Early Trials ramucirumab + SAR408701 Sensitive : C3
CEACAM5 expression	Neuroendocrine Tumor	CEACAM5 expression	Neuroendocrine Tumor	IMMU-130 Sensitive: D – Preclinical IMMU-130 Sensitive : D	IMMU-130 Sensitive: D – Preclinical IMMU-130 Sensitive : D
CEACAM5 expression	Pancreatic Cancer	CEACAM5 expression	Pancreatic Cancer	SAR408701 Sensitive: D – Preclinical SAR408701 Sensitive : D	SAR408701 Sensitive: D – Preclinical SAR408701 Sensitive : D
CEACAM5 expression	Solid Tumor	CEACAM5 expression	Solid Tumor	BDC-2034 Sensitive: D – Preclinical BDC-2034 Sensitive : D	BDC-2034 Sensitive: D – Preclinical BDC-2034 Sensitive : D
CEACAM5 expression	Prostate Cancer	CEACAM5 expression	Prostate Cancer	IMMU-130 Sensitive: D – Preclinical IMMU-130 Sensitive : D	IMMU-130 Sensitive: D – Preclinical IMMU-130 Sensitive : D
KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	SAR408701 Sensitive: D – Preclinical SAR408701 Sensitive : D	SAR408701 Sensitive: D – Preclinical SAR408701 Sensitive : D

CEACAM5-targeted antibody-drug conjugate

CEACAM5-targeted antibody-drug conjugate

Associations(15)

Associations
(15)